{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/management/management/","result":{"pageContext":{"chapter":{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field bc62e3b5-5c2f-4b29-92ac-72bcd07480d7 --><h2>Scenario: Management</h2><!-- end field bc62e3b5-5c2f-4b29-92ac-72bcd07480d7 -->","summary":"Covers the management and referral of children and adults with allergic rhinitis in primary care.","htmlStringContent":"<!-- begin item 4393266c-d867-4b0b-85f7-0cf0f5201e66 --><!-- begin field 128066f3-7f69-47cd-8910-acbc0157e415 --><p>From age 24 months onwards.</p><!-- end field 128066f3-7f69-47cd-8910-acbc0157e415 --><!-- end item 4393266c-d867-4b0b-85f7-0cf0f5201e66 -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"f3131045-22ca-572d-8345-a1b43c7e9c7a","slug":"self-management-strategies","fullItemName":"Self-management strategies","depth":3,"htmlHeader":"<!-- begin field 131a2def-b4d8-491b-92eb-c9974b6a06c7 --><h3>What self-management strategies should I advise?</h3><!-- end field 131a2def-b4d8-491b-92eb-c9974b6a06c7 -->","summary":null,"htmlStringContent":"<!-- begin item 97778796-463b-4139-986a-c00999df5911 --><!-- begin field 02b5656f-dab8-4e4c-b5ab-3064d1ee568b --><p><strong>If a person has a <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/diagnosis/diagnosis/\">diagnosis</a> of allergic rhinitis:</strong></p><ul><li><strong>Provide advice on sources of information and support, such as:</strong><ul><li>The Allergy UK factsheets on <a data-hyperlink-id=\"8f1be765-23c0-4258-b52e-a9650095cf35\" href=\"https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/11-hay-fever-allergic-rhinitis\" target=\"_blank\">Hay fever (Allergic Rhinitis)</a> and <a data-hyperlink-id=\"4e4bf4fa-61b9-4905-bae9-a965016046ef\" href=\"https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/320-improving-your-indoor-air-quality\" target=\"_blank\">Improving your indoor air quality</a>.</li><li>The NHS patient information leaflets <a data-hyperlink-id=\"239e4418-6945-4034-9d60-a9650095cf74\" href=\"https://www.nhs.uk/conditions/allergic-rhinitis/\" target=\"_blank\">Allergic rhinitis</a> and <a data-hyperlink-id=\"3f8e68f8-9330-433a-8236-a9650095cf83\" href=\"https://www.nhs.uk/conditions/hay-fever/\" target=\"_blank\">Hay fever</a>.</li><li>The patient information leaflet <a data-hyperlink-id=\"2a398e87-6e64-4b8c-8d66-a9650095cf91\" href=\"https://patient.info/health/hay-fever-leaflet\" target=\"_blank\">Hay Fever and Seasonal Allergies</a> available on the <a data-hyperlink-id=\"225c538f-4716-4e57-b51d-a9650095cf99\" href=\"https://patient.info/\" target=\"_blank\">www.patient.info</a> website.</li></ul></li><li><strong>Advise the person to consider the use of nasal irrigation with saline</strong> to rinse the nasal cavity using a spray, pump, or squirt bottle, which can be bought over-the-counter.</li><li><strong>Provide advice on allergen avoidance techniques</strong> if there is a specific identified <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/background-information/causes/\">causative allergen</a>:<ul><li><strong>For people with grass pollen allergy,</strong> advise to:<ul><li>Avoid walking in grassy, open spaces, particularly during the early morning, early evening, and during mowing, when the pollen count is high.</li><li>Avoid drying washing outdoors when the pollen count is high.</li><li>Keep windows shut in cars and buildings.</li><li>Plan holidays to avoid the pollen season, where possible.</li><li>Shower or wash hair following high pollen exposures.</li></ul></li><li><strong>For people with confirmed house dust mite allergy</strong> following <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#allergy-testing\">allergy testing</a>, advise to:<ul><li><em>Not</em> fit mattresses, pillows, and duvets with house dust mite impermeable covers.</li><li>Use synthetic pillows and acrylic duvets, and keep furry toys off the bed.</li><li>Wash all bedding and furry toys at least once a week at high temperatures.</li><li>Choose wooden or hard floor surfaces instead of carpets, if possible.</li><li>Fit blinds that can be wiped clean instead of curtains. Surfaces should be wiped regularly with a clean, damp cloth.</li></ul></li><li><strong>For people with confirmed animal allergy</strong> following <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#allergy-testing\">allergy testing</a>, advise to:<ul><li>Ideally not allow the animal in the house. If this is not acceptable or possible, advise restricting their presence to the kitchen.</li><li>Wash the animal and any surfaces they are in contact with, regularly.</li></ul></li><li><strong>For people with occupational allergy, </strong>advise to:<ul><li>Eliminate or reduce exposure to sensitizing allergens in the workplace, for example, by using latex-free gloves, wearing protective clothing, or a dust mask.</li><li>Ensure that their work environment is adequately ventilated and/or relocating to lower exposure areas in the workplace.</li><li>Use less hazardous chemicals, if possible and appropriate.</li></ul></li></ul></li></ul><!-- end field 02b5656f-dab8-4e4c-b5ab-3064d1ee568b --><!-- end item 97778796-463b-4139-986a-c00999df5911 -->","subChapters":[{"id":"834de772-067c-5ab9-b037-9540fc416620","slug":"basis-for-recommendation-b07","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9e09e9cc-d248-47ec-887a-db3e4191b292 --><h4>Basis for recommendation</h4><!-- end field 9e09e9cc-d248-47ec-887a-db3e4191b292 -->","summary":null,"htmlStringContent":"<!-- begin item b0783f66-0828-4770-b45a-e35fda42643b --><!-- begin field 01720ec8-c94e-466f-acd5-d749a857fde8 --><p>The recommendations on self-management strategies are largely based on the Allergic Rhinitis and its Impact on Asthma (ARIA) international guidelines (2010 revision) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], expert opinion in the British Society of Allergy and Clinical Immunology guideline <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], a primary care expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>], the European Academy of Allergy and Clinical Immunology position paper <em>Paediatric rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>], the Cochrane systematic reviews <em>House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Nurmatov, 2012</a>] and <em>Saline irrigation for allergic rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Head, 2018</a>], and expert opinion in review articles on allergic rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Saleh, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>] and occupational rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Stevens, 2015</a>].</p><h5>Advice on nasal saline irrigation</h5><ul><li>The recommendation on considering nasal irrigation with saline is based on limited evidence in the literature that it may provide some symptom relief, and is unlikely to cause significant harm.<ul><li>The BSACI guideline notes that saline irrigation in children and adults is well tolerated, inexpensive, easy to use, and is unlikely to cause adverse effects. It has a small beneficial effect in symptom reduction and may reduce the need for subsequent drug treatment. In addition, it is a safe and effective option in pregnancy and while breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].</li><li>This approach is supported by a primary care expert consensus statement, which found nasal irrigation to be a safe, inexpensive treatment which may reduce seasonal rhinitis symptoms in children and adults. It concluded, however, that it has a limited role in the management of allergic rhinitis, and there are limited data to support its use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li><li>A Cochrane systematic review of 14 randomized controlled trials (RCTs, n = 747) compared the effect of saline nasal irrigation with isotonic or hypertonic solution, with no irrigation or other drug treatments (intranasal corticosteroids or oral antihistamines) for children and adults with allergic rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Head, 2018</a>].<ul><li>It found low-quality evidence that saline irrigation may improve patient‐reported disease severity compared with no irrigation at up to three months, with no reported adverse effects. It is uncertain if saline irrigation in addition to drug treatment improved patient-reported disease severity compared with drug treatment alone at up to three months (very low-quality evidence).</li><li>It concluded that the included studies were generally small, and used different outcome measures, however, saline irrigation may provide a cheap, safe and acceptable alternative to some drug treatments in the management of allergic rhinitis.</li></ul></li><li>A review article found some evidence from small trials that saline irrigation improves mucociliary function, reduces mucosal oedema, and decreases inflammatory mediators in allergic rhinitis. It recommended its use in children to reduce symptoms and potentially reduce the need for drug treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>]. This approach is supported by the European position paper, which states saline irrigation may be a useful add-on treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>].</li></ul></li></ul><h5>Advice on grass pollen allergen avoidance</h5><ul><li>The recommendations on grass pollen avoidance are largely pragmatic based on very limited evidence, but are recommended in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>]. They are also supported by the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Advice on house dust mite allergen avoidance</h5><ul><li>The 2010 revision of the ARIA guideline does not recommend the use of single chemical or physical preventative methods to reduce exposure to house dust mites, based on low-quality evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>]. Similarly, the BSACI guideline does not recommend house dust mite avoidance measures such as encasing mattresses, pilllows, and duvets in allergen-impermeable fabric as a single intervention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].<ul><li>This is supported by a Cochrane systematic review of nine RCTs (n = 501) of bedroom environmental house dust mite control measures (including impermeable bedding covers, acaricides, and air filters) compared with placebo or other control measures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Nurmatov, 2012</a>].<ul><li>It found that house dust mite impermeable bedding as an isolated intervention is unlikely to offer benefit. Other interventions may reduce house dust mite load, but this is based on limited evidence, as trials are generally small and of poor methodological quality, with heterogeneity of study design, and differing outcome measures, such that meta-analysis could not be performed.</li></ul></li></ul></li><li>The additional allergen avoidance measures are based on expert opinion in a review article on perennial rhinitis, which also recommends confirmation of house dust mite allergy by skin prick testing prior to the implementation of these potentially burdensome measures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Saleh, 2007</a>].</li></ul><h5>Advice on animal dander allergen avoidance</h5><ul><li>The 2010 revision of the ARIA guideline strongly recommends people with allergic rhinitis caused by animal dander should avoid exposure to these allergens at home, based on very low-quality evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>]. This approach is supported by the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>] and expert opinion in a review article that affected people should be discouraged from having pets in the home [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Saleh, 2007</a>].</li><li>Expert opinion in an additional review article recommends animals should be washed regularly, as should all surfaces in potential contact with animal dander [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>].</li></ul><h5>Advice on occupational allergen avoidance</h5><ul><li>The recommendations on avoidance of occupational allergens is important, as symptoms may be reversible with early diagnosis and avoidance, but may become chronic and irreversible over time [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li><li>The BSACI guideline recommends complete avoidance of exposure to causal agents in cases of occupational allergic rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>]. CKS notes that the 2010 revision of the ARIA guideline recommends immediate and total cessation of exposure to occupational allergen(s) in people with occupational rhinitis <em>and</em> asthma, based on very low-quality evidence, but does not make specific recommendations for people with occupational rhinitis alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>].</li><li>The specific recommendations on reducing workplace exposures are based on expert opinion in a review article, which notes that occupational rhinitis may be a predictor for the future development of occupational asthma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Stevens, 2015</a>]. Optimal management of occupational rhinitis may, therefore, help prevent progression to occupational asthma.</li></ul><!-- end field 01720ec8-c94e-466f-acd5-d749a857fde8 --><!-- end item b0783f66-0828-4770-b45a-e35fda42643b -->","subChapters":[]}]},{"id":"1d9c67e7-22a6-533a-a18c-a9dfa7a100cb","slug":"initial-drug-treatment","fullItemName":"Initial drug treatment","depth":3,"htmlHeader":"<!-- begin field 217247e4-91a8-4b24-9d6d-87c38c5f4c56 --><h3>What initial drug treatments should I recommend?</h3><!-- end field 217247e4-91a8-4b24-9d6d-87c38c5f4c56 -->","summary":null,"htmlStringContent":"<!-- begin item 4518d804-7090-43a2-965d-5fcb177a1e03 --><!-- begin field 944eeaae-c61d-464c-83f4-68d4bbf75005 --><p><strong>If a person has a <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/diagnosis/diagnosis/\">diagnosis</a> of allergic rhinitis, advise on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#self-management-strategies\">self-management strategies</a> and drug treatment options:</strong></p><ul><li><strong>If the person has mild-to-moderate intermittent, or mild persistent symptoms:</strong><ul><li>Advise on the 'as-needed' use of an intranasal antihistamine first-line, or a second-generation, non-sedating oral antihistamine, depending on the person's age and personal preference.<ul><li>Advise that intranasal antihistamines (azelastine) have a faster onset of action and are more effective than oral preparations. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-antihistamines/\">Intranasal antihistamines</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a> for more information on intranasal antihistamines and intranasal <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-antihistamines/#intranasal-spray-drop-technique\">spray and drop technique</a>.</li><li>Oral antihistamine options include loratadine or cetirizine, which may be available over-the-counter. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/oral-antihistamines/\">Oral antihistamines</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>Consider the use of an intranasal chromone such as sodium cromoglicate to be used 'as needed', if antihistamines are contraindicated or not tolerated.<ul><li>Advise that these preparations need to be used up to four times a day. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-cromones/\">Intranasal cromones</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li></ul></li><li><strong>If the person has moderate-to-severe persistent symptoms, or initial drug treatment is ineffective:</strong><ul><li>Prescribe a regular intranasal corticosteroid to be used during periods of allergen exposure.<ul><li>Options include intranasal mometasone furoate, fluticasone furoate, or fluticasone propionate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more prescribing information including different preparations and advice on intranasal spray and drop technique.</li><li>Advise the person that the onset of action is 6–8 hours after the first dose, but the maximal effect may not be seen until after two weeks.</li><li>Nasal drops may be preferred if there is severe nasal obstruction.</li><li>Advise the person not to increase beyond the prescribed dose as there is no evidence of additional benefit, and do not switch to an alternative preparation, as they all have comparable efficacy.</li></ul></li></ul></li><li><strong>If drug treatment provides adequate symptom control, advise the person to continue treatment until they are no longer likely to be exposed to the suspected allergen.</strong> For people allergic to:<ul><li>House dust mite and/or pets in the home — symptoms are usually present throughout the year, requiring ongoing treatment.</li><li>Tree pollens — treatment is usually required from early to late spring.</li><li>Grass pollens — treatment is usually required from late spring to early summer.</li><li>Weed pollens — treatment is usually required from early spring to late autumn.<ul><li>If there are recurrent episodes of symptoms controlled by intranasal corticosteroids, advise the person to restart treatment two weeks before re-exposure to causative allergens.</li><li>If the time of re-exposure is uncertain, such as the start of the pollination season, advise the person to start treatment several weeks before the most likely time of re-exposure.</li></ul></li></ul></li><li><strong>Advise the person to be reviewed after 2–4 weeks</strong> if symptoms persist after initial treatment, as management may need to be stepped up. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#treatment-failure-referral\">Treatment failure and referral</a> for more information.</li></ul><!-- end field 944eeaae-c61d-464c-83f4-68d4bbf75005 --><!-- end item 4518d804-7090-43a2-965d-5fcb177a1e03 -->","subChapters":[{"id":"e6c9bb55-1749-522d-b9e6-3e13e32af090","slug":"basis-for-recommendation-dfc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4c19dbeb-15ad-4bff-927b-84e7874ba592 --><h4>Basis for recommendation</h4><!-- end field 4c19dbeb-15ad-4bff-927b-84e7874ba592 -->","summary":null,"htmlStringContent":"<!-- begin item dfc235cc-28c1-4d4f-821f-93faaf88bd45 --><!-- begin field fcb330c1-d690-45f6-ae2a-60f736e30e1d --><p>The recommendations on initial drug treatment of allergic rhinitis are largely based on the Allergic Rhinitis and its Impact on Asthma (ARIA) international guidelines 2008 publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">ARIA, 2008</a>], 2010 revision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], and 2016 revision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek, 2017</a>]; expert opinion in the British Society of Allergy and Clinical Immunology guideline <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], a primary care expert consensus statement <em>An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>], the European Academy of Allergy and Clinical Immunology position paper <em>Paediatric rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>], and expert opinion in a review article on allergic rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>].</p><h5>Managing mild-to-moderate intermittent, or mild persistent symptoms</h5><ul><li>The recommendations on the first-line management of allergic rhinitis with an intranasal (or oral) antihistamine are largely based on the 2010 revision of the ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>], and an expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].<ul><li>The therapeutic effect of intranasal antihistamines is generally superior to oral preparations in reducing rhinitis symptoms and nasal obstruction, and they have a faster onset of action for controlling breakthrough symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].</li><li>CKS notes that the 2016 revision of the ARIA international guideline recommends the use of either intranasal or oral antihistamines for seasonal and persistent rhinitis symptoms, based on low-quality evidence, and states the choice of treatment will depend on personal preference, local availability, and cost. If oral antihistamines are being considered, the 2010 revision recommends the use of new generation non-sedating oral antihistamines first-line.</li></ul></li><li>The recommendation on the use of cromones such as sodium cromoglicate is based on the 2010 revision of the ARIA guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], and the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>].<ul><li>The ARIA guideline recommends intranasal cromones on the basis of moderate-quality evidence, however, it notes that the need to apply the preparation four times a day is likely to reduce adherence with treatment and thereby reduce efficacy. It also notes these preparations are likely to be less effective than intranasal anthistamines.</li><li>The BSACI guideline states these agents may be used for people with mild, intermittent symptoms or with limited allergen exposure. It notes cromones may be weakly effective for rhinitis symptoms with some effect on nasal obstruction, and may be particularly useful for people with limited drug treatment options, such as pregnant or breastfeeding women.</li><li>The European position paper notes that intranasal sodium cromoglicate may be an effective treatment based on old studies, but the need for frequent application may reduce concordance.</li></ul></li><li>The recommendation to educate the person on the correct intranasal spray or drop technique is based on the fact that treatment failure may be related to incorrect administration technique [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li></ul><h5>Managing moderate-to-severe persistent symptoms, or non-response to initial treatment</h5><ul><li>The recommendation to prescribe intranasal corticosteroids regularly first-line for moderate-to-severe disease is based on evidence-based recommendations in the ARIA international guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek, 2017</a>], expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], and the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>].<ul><li>The 2010 revision of the ARIA guideline recommends intranasal corticosteroids for the treatment of allergic rhinitis in children and adults, based on high-quality and moderate-quality evidence respectively. It also notes these preparations are more effective than oral antihistamines in children and adults with seasonal and persistent symptoms. The BSACI guideline also states that meta-analysis found intranasal corticosteroids to be superior to oral antihistamines.</li><li>The 2016 revision of the ARIA guideline notes that intranasal corticosteroid monotherapy provides a greater reduction in seasonal and persistent symptoms than intranasal antihistamine monotherapy, based on moderate- and low-quality evidence respectively.</li></ul></li><li>The recommendations on the choice of intranasal corticosteroid preparations are based on expert opinion in the BSACI guideline and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>], as these formulations have negligible systemic absorption, reducing the likelihood of adverse effects.</li><li>The recommendations on the onset of action and the use of intranasal drops for severe obstruction are based on expert opinion in the BSACI guideline.</li><li>The recommendations not to increase the dose of intranasal corticosteroid as there is a recognised ceiling effect, and not to switch preparations as they all have comparable efficacy, are based on expert opinion in a consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li></ul><h5>Advice on durations of drug treatment</h5><ul><li>The information on the timings of likely exposure to causative allergens is extrapolated from information in the 2008 ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">ARIA, 2008</a>].</li><li>The recommendation to start intranasal corticosteroids two weeks prior to a known allergen season is based on the fact that the maximal effect of intranasal corticosteroids may not be seen until two weeks after starting treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].</li></ul><h5>Arranging review if symptoms persist</h5><ul><li>The recommendation to arrange review if symptoms persist after 2–4 weeks is based on an expert consensus statement, which considers a two-week trial appropriate to assess initial response to antihistamines, and a four-week trial appropriate for intranasal corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li></ul><!-- end field fcb330c1-d690-45f6-ae2a-60f736e30e1d --><!-- end item dfc235cc-28c1-4d4f-821f-93faaf88bd45 -->","subChapters":[]}]},{"id":"bb3cf1f0-9329-5850-88b3-11576eb08fca","slug":"treatment-failure-referral","fullItemName":"Treatment failure and referral","depth":3,"htmlHeader":"<!-- begin field 73eee309-f744-4676-82fd-d444abfe40d9 --><h3>How should I manage treatment failure?</h3><!-- end field 73eee309-f744-4676-82fd-d444abfe40d9 -->","summary":null,"htmlStringContent":"<!-- begin item 5f32c92e-104b-46d9-9b50-f69846e0243d --><!-- begin field ff1d1526-4961-406e-b361-473e249988ff --><p><strong>If a person has uncontrolled symptoms following initial <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#self-management-strategies\">self-management strategies</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#initial-drug-treatment\">drug treatment</a>:</strong></p><ul><li><strong>Consider causes for treatment failure.</strong><ul><li>Check compliance with self-management strategies, if appropriate.</li><li>Check compliance with initial drug treatments and/or the <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-antihistamines/#intranasal-spray-drop-technique\">correct technique</a> when using intranasal sprays or drops.</li><li>An <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/diagnosis/differential-diagnosis/\">alternative diagnosis</a> or non-allergic cause for symptoms.</li></ul></li><li><strong>Consider stepping up treatment</strong> if a person has refractory symptoms while using a regular intranasal corticosteroid preparation.<ul><li>If nasal congestion is a problem, add in a short-term intranasal decongestant such as ephedrine or xylometazoline for up to 5–7 days, depending on the person's age and preparation used.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-decongestants/\">Intranasal decongestants</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>If there is persistent watery rhinorrhoea despite combined use of an intranasal corticosteroid and oral antihistamine, add in an intranasal anticholinergic such as ipratropium bromide.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-anticholinergics/\">Intranasal anticholinergics</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>If there is persistent nasal itching and sneezing, options are to add in an oral antihistamine to be used regularly rather than 'as needed', or to prescribe a combination preparation containing an intranasal antihistamine (azelastine) and intranasal corticosteroid (fluticasone propionate) such as Dymista<sup>®</sup> spray, if monotherapy with either an antihistamine or intranasal corticosteroid is ineffective.<ul><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/oral-antihistamines/\">Oral antihistamines</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/intranasal-antihistamines/\">Intranasal antihistamines</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a>, and the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li><li>Note: combined use of an intranasal <em>and</em> oral antihistamine is not recommended.</li></ul></li><li>If the person has ongoing symptoms and a history of asthma, consider adding in a leukotriene receptor antagonist such as montelukast to an oral or intranasal antihistamine.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/oral-leukotriene-receptor-antagonists/\">Oral leukotriene receptor antagonists</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li></ul></li><li><strong>If the person has severe, uncontrolled symptoms that are significantly affecting quality of life, consider prescribing a short course of oral corticosteroids</strong> to provide rapid symptom relief, such as:<ul><li>For adults — prednisolone 0.5 mg/kg in the morning for 5–10 days.</li><li>For children — prednisolone 10–15 mg in the morning for 3–7 days.<ul><li>Advise the person to continue using an intranasal corticosteroid preparation, to allow improved intranasal drug penetration.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a> for more prescribing information.</li></ul></li></ul></li><li><strong>If drug treatment provides adequate symptom control, advise the person to continue treatment until they are no longer likely to be exposed to the suspected allergen.</strong> For people allergic to:<ul><li>House dust mite and/or pets in the home — symptoms are usually present throughout the year, requiring ongoing treatment.</li><li>Tree pollens — treatment is usually required from early to late spring.</li><li>Grass pollens — treatment is usually required from late spring to early summer.</li><li>Weed pollens — treatment is usually required from early spring to late autumn.<ul><li>If there are recurrent episodes of symptoms controlled by intranasal corticosteroids, advise the person to restart treatment two weeks before re-exposure to causative allergens.</li><li>If the time of re-exposure is uncertain, such as the start of the pollination season, advise the person to start treatment several weeks before the most likely time of re-exposure.</li></ul></li></ul></li><li><strong>Consider arranging referral for specialist assessment and management to an allergy or ear, nose, and throat (ENT) specialist if:</strong><ul><li>There are red flag features such as unilateral symptoms, blood-stained nasal discharge, recurrent epistaxis, or nasal pain — arrange an urgent two-week wait referral to ENT.</li><li>There is predominant nasal obstruction and/or a structural abnormality such as deviated nasal septum which makes intranasal drug treatment difficult — arrange referral to ENT.</li><li>There are persistent symptoms despite optimal management in primary care — consider referral to an allergy specialist for <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#allergy-testing\">allergy testing</a> and possible <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#immunotherapy-treatment\">immunotherapy treatment</a>, depending on local referral pathways and availability.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#self-management-strategies\">Allergen avoidance techniques</a> such as house dust mite or animal dander avoidance are being considered — skin prick <a class=\"topic-reference internal-reference\" href=\"/topics/allergic-rhinitis/management/management/#allergy-testing\">allergy testing</a> to confirm the responsible allergen may be needed.</li><li>The diagnosis is uncertain — consider referral to an allergy or ENT specialist, depending on clinical judgement.</li></ul></li></ul><!-- end field ff1d1526-4961-406e-b361-473e249988ff --><!-- end item 5f32c92e-104b-46d9-9b50-f69846e0243d -->","subChapters":[{"id":"f5f6424f-fa13-535a-a4d7-4358bf710d5a","slug":"allergy-testing","fullItemName":"Allergy testing","depth":4,"htmlHeader":"<!-- begin field 1fddad29-3c6a-4cec-a543-a96600c121c2 --><h4>Allergy testing</h4><!-- end field 1fddad29-3c6a-4cec-a543-a96600c121c2 -->","summary":null,"htmlStringContent":"<!-- begin item 5c8c2593-2f2c-4e1c-a222-a96600c12162 --><!-- begin field b73755bc-5ff6-420e-80f5-a96600c121c2 --><ul><li><strong>Allergy testing may involve skin prick testing or measuring the levels of serum-specific immunoglobulin (Ig) E to allergens such as house dust mites, pollen, and animal dander (radioallergosorbent test [RAST]).</strong><ul><li>Skin prick testing may help to differentiate between allergic and non-allergic rhinitis, and has a high negative predictive value. It has a better positive predictive value than serum testing, and provides immediate results, however results may be suppressed by recent antihistamine, tricyclic antidepressant (TCA), and topical corticosteroid use. Interestingly, at least 15% of people with a positive skin prick test do not develop symptoms on exposure to the relevant allergen, and therefore positive tests alone do not confirm the causative allergen if there is no supportive history.</li><li>Serum testing may be used when skin prick testing is not possible, or skin prick testing taken with the clinical history give equivocal results.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>] </p><!-- end field b73755bc-5ff6-420e-80f5-a96600c121c2 --><!-- end item 5c8c2593-2f2c-4e1c-a222-a96600c12162 -->","subChapters":[]},{"id":"442de1a7-60d8-5d6b-8615-cdacbc0fc50a","slug":"immunotherapy-treatment","fullItemName":"Immunotherapy treatment","depth":4,"htmlHeader":"<!-- begin field 4184b445-af69-45ba-8d78-a96600c15e53 --><h4>Immunotherapy treatment</h4><!-- end field 4184b445-af69-45ba-8d78-a96600c15e53 -->","summary":null,"htmlStringContent":"<!-- begin item d5ae8fba-1747-41aa-bb9e-a96600c15cd4 --><!-- begin field d36e74ab-3894-46a0-87c4-a96600c15e53 --><ul><li><strong>Specialist immunotherapy may be appropriate for people with symptoms on allergen exposure, objective confirmation of IgE sensitivity, and persistent symptoms</strong> predominantly due to one allergen such as grass pollen or house dust mite. Treatment may be by subcutaneous injection or sublingual, and involves exposing the person to increasing amounts of allergen to induce clinical and immunological tolerance.<ul><li>Subcutaneous therapy may involve weekly initial dosing regimens followed by 4–6 weekly maintenance injections usually for 3 years. Pre-seasonal immunotherapy may be effective for pollen allergy.</li><li>Sublingual immunotherapy may be an alternative for the treatment of allergic rhinitis due to one or more species of grass pollen and house dust mite. If tolerated, subsequent doses may be self-administered daily at home for, usually, 3 years.<ul><li>Adverse effects are generally short-lived: subcutaneous immunotherapy may cause itching, redness, and swelling at the injection site; sublingual immunotherapy may cause oropharyngeal itching and localized swelling which typically settles with repeated dosing.</li><li>Immunotherapy is the only treatment that can modify disease progression, with long-term remission possible following the end of treatment. Subcutaneous immunotherapy in children with seasonal rhinitis may reduce the risk of progression to asthma, and may prevent the development of new sensitizations.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Slovick, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>]</p><!-- end field d36e74ab-3894-46a0-87c4-a96600c15e53 --><!-- end item d5ae8fba-1747-41aa-bb9e-a96600c15cd4 -->","subChapters":[]},{"id":"1bea6e8c-bc5a-5dc1-bbe7-2269a851674e","slug":"basis-for-recommendation-f2d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e0906ab0-55ec-4bb1-8fca-fdc4ff3162e1 --><h4>Basis for recommendation</h4><!-- end field e0906ab0-55ec-4bb1-8fca-fdc4ff3162e1 -->","summary":null,"htmlStringContent":"<!-- begin item f2d59e43-7d9e-486b-a7c8-ba015468d97c --><!-- begin field 6e38b8aa-27a0-4de5-a606-6586514e41c2 --><p>The recommendations on treatment failure and referral are largely based on the Allergic Rhinitis and its Impact on Asthma (ARIA) international guidelines 2008 publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">ARIA, 2008</a>], 2010 revision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], and 2016 revision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek, 2017</a>], expert opinion in the British Society of Allergy and Clinical Immunology guideline <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], a primary care expert consensus statement <em>An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>], the European Academy of Allergy and Clinical Immunology position paper <em>Paediatric rhinitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>], and expert opinion in review articles on allergic rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Saleh, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>].</p><h5>Managing potential causes of treatment failure</h5><ul><li>The information on potential causes of treatment failure are based on expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>] and an expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li></ul><h5>Adding in a short-term intranasal decongestant</h5><ul><li>The recommendation to use a short-term intranasal decongestant is largely based on the 2010 revision of the ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>] and in the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>].<ul><li>The ARIA guideline recommends very short-term use of an intranasal decongestant for up to five days in adults with severe nasal obstruction, based on very low-quality evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>].</li><li>CKS notes that the British National Formulary (BNF) recommends the use of intranasal decongestants for 5–7 days, depending on the age of the person and the preparation used, in order to minimize the risk of rebound congestion and rhinitis medicamentosa associated with longer term use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]. CKS also notes that the BSACI guideline recommends use of an intranasal decongestant for less than 10 days, and the European position paper recommends use for a 'few days' for severe nasal obstruction.</li><li>The BSACI guideline notes these agents may relieve nasal congestion symptoms faster and more effectively than intranasal corticosteroids. They may also allow the delivery of intranasal preparations beyond the inferior turbinates, thereby improving other intranasal drug efficacy.</li></ul></li></ul><h5>Adding in an intranasal anticholinergic</h5><ul><li>The recommendation to use an intranasal anticholinergic agent such as ipratropium bromide is based on expert opinion in the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>] and the BSACI guideline, which states that these agents may have an 'add-on' role if watery rhinorrhoea persists despite treatment with intranasal corticosteroids and antihistamines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].</li><li>This approach is supported by the 2010 revision of the ARIA international guideline, which recommends intranasal ipratropium bromide for the treatment of rhinorrhoea, based on moderate-quality evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>], and also by a UK expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].</li></ul><h5>Adding in an oral antihistamine</h5><ul><li>The recommendation to consider adding in an oral antihistamine to an intranasal corticosteroid is extrapolated from the 2016 revision of the ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek, 2017</a>], expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>] and an expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].<ul><li>The ARIA guideline suggests this combination may be considered if there are moderate-to-severe intermittent symptoms which are not well controlled with intranasal corticosteroid monotherapy, based on low-quality evidence. It stresses the oral antihistamine should be used regularly rather than 'as needed', and this is supported by the BSACI guideline.</li></ul></li><li>The recommendation not to use both an intranasal and oral antihistamine is based on the BSACI guideline, which states that there is no additional advantage in using both agents together for rhinitis symptoms.</li></ul><h5>Prescribing a combination intranasal antihistamine and corticosteroid preparation</h5><ul><li>The recommendation to consider the use of a combination intranasal antihistamine and corticosteroid for refractory symptoms is based on the 2016 revision of the ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek, 2017</a>], the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>], and an expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>].<ul><li>The ARIA guideline recommends the option of combination treatment, particularly as this may act faster than intranasal corticosteroid monotherapy, based on low- to moderate-quality evidence. It also notes that this combination is more effective for symptom reduction than the use of intranasal antihistamine monotherapy, based on low-quality evidence.</li><li>The BSACI guideline and expert consensus statement also recommend considering combination therapy second-line (prescribed as Dymista<sup>®</sup> intranasal spray) if the person is more than 12 years old with moderate or severe seasonal or persistent symptoms if monotherapy with either agent is not effective. In addition, the BSACI guideline suggests concordance with treatment may be higher when the drug regimen is simple, and it found combination therapy is more effective than using either agent alone.</li></ul></li></ul><h5>Adding in an oral leukotriene receptor antagonist</h5><ul><li>The recommendation to consider the use of a leukotriene receptor antagonist is extrapolated from the 2016 revision of the ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek, 2017</a>] and expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>] and in the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>].<ul><li>The ARIA guideline notes that some people with seasonal allergic rhinitis and asthma (especially exercise-induced disease) may benefit from a leukotriene receptor antagonist if they have ongoing symptoms, based on moderate-quality evidence.</li><li>The BSACI guideline cites limited evidence that these agents may have a role for people with refractory seasonal allergic rhinitis symptoms who also have a history of asthma, in addition to an oral or topical antihistamine.</li><li>The European position states that montelukast monotherapy is effective in both seasonal and perennial allergic rhinitis in two small studies in children.</li></ul></li></ul><h5>Prescribing oral corticosteroids for severe refractory symptoms</h5><ul><li>The recommendation to consider prescribing a short course of oral corticosteroids for severe refractory rhinitis symptoms is based on the 2010 revision of the ARIA international guideline which found very low-quality evidence to support this approach. It recommends this treatment for a few days as a 'last resort' when combinations of other treatments are ineffective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Brozek et al, 2010</a>].</li><li>The BSACI guideline notes there is no consensus in the literature on the optimal dose and duration of oral corticosteroid treatment, but suggests a dose for adults of 0.5 mg/kg in the morning, for 5–10 days. It also advises the person to continue using an intranasal corticosteroid preparation, to allow optimal intranasal cavity drug penetration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].</li><li>The recommended oral corticosteroid doses for children are based on the European position paper, which suggests a short course of 10–15 mg of prednisolone for 3–7 days for school-age children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>].</li></ul><h5>Advice on durations of drug treatment</h5><ul><li>The information on the timings of likely exposure to causative allergens is extrapolated from information in the 2008 ARIA international guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">ARIA, 2008</a>].</li><li>The recommendation to start intranasal corticosteroids two weeks prior to a known allergen season is based on the fact that the maximal effect of intranasal corticosteroids may not be seen until two weeks after starting treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>].</li></ul><h5>Arranging specialist referral</h5><ul><li>The recommendations to consider referral to an ear, nose, and throat (ENT) specialist if there are red flag symptoms or structural abnormalities are based on expert opinion in the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Scadding, 2017</a>] and in the European position paper [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Roberts, 2013</a>], as nasendoscopy may allow visualisation of the posterior nasal cavity and middle meatus. This is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>].</li><li>The recommendation to consider referral to an allergy specialist for possible allergy testing to identify specific allergen triggers which can then be avoided and possible immunotherapy, is based on an expert consensus statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Lipworth, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Saleh, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">Barr, 2014</a>]. Interestingly, the expert consensus statement notes that the majority of people with allergic rhinitis in primary care can be managed without formal identification of the specific allergen trigger.</li></ul><!-- end field 6e38b8aa-27a0-4de5-a606-6586514e41c2 --><!-- end item f2d59e43-7d9e-486b-a7c8-ba015468d97c -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}